Does the media prefer MRK or SMMT?

In the previous week, Merck & Co., Inc. had 11 more articles in the media than Summit Therapeutics. MarketBeat recorded 33 mentions for Merck & Co., Inc. and 22 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 0.43 beat Summit Therapeutics' score of 0.42 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 12 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, LPA or SMMT?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Logistic Properties of the Americas $50.13M 1.89 $10.50M N/A N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is RVMD or SMMT more profitable?

Revolution Medicines' return on equity of -88.20% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -88.20% -57.85% Summit Therapeutics N/A -168.94% -141.92%

Does the media prefer RVMD or SMMT?

In the previous week, Summit Therapeutics had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 22 mentions for Summit Therapeutics and 14 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.57 beat Summit Therapeutics' score of 0.42 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is BIIB or SMMT more profitable?

Biogen has a net margin of 8.32% compared to Summit Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor BIIB or SMMT?

In the previous week, Summit Therapeutics had 10 more articles in the media than Biogen. MarketBeat recorded 22 mentions for Summit Therapeutics and 12 mentions for Biogen. Biogen's average media sentiment score of 1.02 beat Summit Therapeutics' score of 0.42 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 5 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to SMMT or ALNY?

In the previous week, Summit Therapeutics had 14 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for Summit Therapeutics and 8 mentions for Alnylam Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.42 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Summit Therapeutics (SMMT) Competitors

$16.75 +0.06 (+0.36%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$16.80 +0.05 (+0.27%)

As of 10/2/2026 07:59 PM Eastern

Compare

SMMT vs. MRK, LPA, RVMD, BIIB, and ALNY

Should you buy Summit Therapeutics stock or one of its competitors? Summit Therapeutics's main competitors and comparable companies include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size.

How does Summit Therapeutics compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Merck & Co., Inc. has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Merck & Co., Inc. has a net margin of 4.77% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 16.73% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Merck & Co., Inc. had 11 more articles in the media than Summit Therapeutics. MarketBeat recorded 33 mentions for Merck & Co., Inc. and 22 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 0.43 beat Summit Therapeutics' score of 0.42 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	12 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$66.57B	5.35	$18.25B	$1.25	115.39
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Merck & Co., Inc. currently has a consensus target price of $145.76, suggesting a potential upside of 1.06%. Summit Therapeutics has a consensus target price of $28.61, suggesting a potential upside of 70.79%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	11 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.59
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Merck & Co., Inc. beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Logistic Properties of the Americas (NYSEAMERICAN:LPA) and Summit Therapeutics (NASDAQ:SMMT) are related companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Logistic Properties of the Americas presently has a consensus target price of $7.50, suggesting a potential upside of 150.84%. Summit Therapeutics has a consensus target price of $28.61, suggesting a potential upside of 70.79%. Given Logistic Properties of the Americas' higher probable upside, research analysts clearly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, Summit Therapeutics had 18 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 22 mentions for Summit Therapeutics and 4 mentions for Logistic Properties of the Americas. Logistic Properties of the Americas' average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.42 indicating that Logistic Properties of the Americas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Logistic Properties of the Americas	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Logistic Properties of the Americas has a net margin of 30.97% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 0.46% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Logistic Properties of the Americas	30.97%	0.46%	0.21%
Summit Therapeutics	N/A	-168.94%	-141.92%

42.7% of Logistic Properties of the Americas shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 32.0% of Logistic Properties of the Americas shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Logistic Properties of the Americas has a beta of 5.45, indicating that its share price is 445% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Logistic Properties of the Americas	$50.13M	1.89	$10.50M	N/A	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Summit Therapeutics had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 22 mentions for Summit Therapeutics and 14 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.57 beat Summit Therapeutics' score of 0.42 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market.

Revolution Medicines' return on equity of -88.20% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summit Therapeutics has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,824.80	-$1.13B	-$8.82	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Revolution Medicines currently has a consensus price target of $234.33, suggesting a potential upside of 13.40%. Summit Therapeutics has a consensus price target of $28.61, suggesting a potential upside of 70.79%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Revolution Medicines beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market.

87.9% of Biogen shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics had 10 more articles in the media than Biogen. MarketBeat recorded 22 mentions for Summit Therapeutics and 12 mentions for Biogen. Biogen's average media sentiment score of 1.02 beat Summit Therapeutics' score of 0.42 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	5 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Biogen currently has a consensus target price of $230.14, suggesting a potential upside of 4.67%. Summit Therapeutics has a consensus target price of $28.61, suggesting a potential upside of 70.79%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Biogen has a net margin of 8.32% compared to Summit Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Summit Therapeutics	N/A	-168.94%	-141.92%

Biogen has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.28	$1.29B	$5.65	38.92
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

Biogen beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Summit Therapeutics (NASDAQ:SMMT) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Summit Therapeutics presently has a consensus price target of $28.61, indicating a potential upside of 70.79%. Alnylam Pharmaceuticals has a consensus price target of $366.90, indicating a potential upside of 66.99%. Given Summit Therapeutics' higher probable upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summit Therapeutics has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

In the previous week, Summit Therapeutics had 14 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for Summit Therapeutics and 8 mentions for Alnylam Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.42 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Summit Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Alnylam Pharmaceuticals	$3.71B	7.92	$313.75M	$5.38	40.84

Summary

Alnylam Pharmaceuticals beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.37B	$3.87B	$7.14B	$13.22B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	N/A	13.13	275.97	26.04
Price / Sales	N/A	1,430.61	672.86	109.50
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	19.71	16.63	10.93	6.31
Net Income	-$1.08B	-$22.71M	$3.51B	$362.16M
7 Day Performance	7.30%	-2.99%	-2.00%	-1.66%
1 Month Performance	-2.22%	-10.60%	-6.15%	-4.50%
1 Year Performance	-21.84%	19.44%	7.44%	2.06%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	2.8837 of 5 stars	$16.75 +0.4%	$28.61 +70.8%	-19.7%	$13.37B	N/A	N/A	265	Analyst Forecast
MRK Merck & Co., Inc.	3.5237 of 5 stars	$148.75 +0.5%	$154.24 +3.7%	+61.3%	$365.09B	$65.01B	119.00	75,000	Analyst Forecast
LPA Logistic Properties of the Americas	4.3015 of 5 stars	$2.91 +3.2%	$7.50 +157.7%	-33.6%	$89.16M	$50.13M	5.39	36	Short Interest Increase Gap Up
RVMD Revolution Medicines	3.2443 of 5 stars	$204.97 +2.6%	$230.15 +12.3%	+352.2%	$42.84B	$11.58M	N/A	883	Insider Trade Analyst Revision
BIIB Biogen	3.4087 of 5 stars	$227.60 +0.5%	$230.14 +1.1%	+41.6%	$33.45B	$9.89B	40.28	7,500	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, BIIB, and ALNY

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Summary

How does Summit Therapeutics compare to Biogen?

Summary

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, BIIB, and ALNY

How does Summit Therapeutics compare to Merck & Co., Inc.?

Which has more risk & volatility, MRK or SMMT?

Is MRK or SMMT more profitable?

Does the media prefer MRK or SMMT?

Do insiders & institutionals hold more shares of MRK or SMMT?

Which has stronger earnings & valuation, MRK or SMMT?

Do analysts recommend MRK or SMMT?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Do analysts recommend LPA or SMMT?

Does the media prefer LPA or SMMT?

Is LPA or SMMT more profitable?

Do insiders and institutionals hold more shares of LPA or SMMT?

Which has more volatility & risk, LPA or SMMT?

Which has better valuation & earnings, LPA or SMMT?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Does the media prefer RVMD or SMMT?

Do institutionals & insiders hold more shares of RVMD or SMMT?

Which has more volatility & risk, RVMD or SMMT?

Is RVMD or SMMT more profitable?

Which has better earnings & valuation, RVMD or SMMT?

Do analysts rate RVMD or SMMT?

Summary

How does Summit Therapeutics compare to Biogen?

Which has more risk & volatility, BIIB or SMMT?

Do institutionals and insiders hold more shares of BIIB or SMMT?

Does the media favor BIIB or SMMT?

Do analysts recommend BIIB or SMMT?

Is BIIB or SMMT more profitable?

Which has preferable earnings & valuation, BIIB or SMMT?

Summary

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts rate SMMT or ALNY?

Which has more volatility and risk, SMMT or ALNY?

Does the media refer more to SMMT or ALNY?

Is SMMT or ALNY more profitable?

Do insiders and institutionals hold more shares of SMMT or ALNY?

Which has better valuation and earnings, SMMT or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools